GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Edwards Lifesciences Corp (NYSE:EW) » Definitions » Cash Ratio

Edwards Lifesciences (Edwards Lifesciences) Cash Ratio

: 1.38 (As of Dec. 2023)
View and export this data going back to 2000. Start your Free Trial

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Edwards Lifesciences's Cash Ratio for the quarter that ended in Dec. 2023 was 1.38.

Edwards Lifesciences has a Cash Ratio of 1.38. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Edwards Lifesciences's Cash Ratio or its related term are showing as below:

EW' s Cash Ratio Range Over the Past 10 Years
Min: 0.94   Med: 1.5   Max: 3.38
Current: 1.38

During the past 13 years, Edwards Lifesciences's highest Cash Ratio was 3.38. The lowest was 0.94. And the median was 1.50.

EW's Cash Ratio is ranked better than
52.21% of 858 companies
in the Medical Devices & Instruments industry
Industry Median: 1.27 vs EW: 1.38

Edwards Lifesciences Cash Ratio Historical Data

The historical data trend for Edwards Lifesciences's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edwards Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.68 1.57 1.42 1.19 1.38

Edwards Lifesciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.19 1.16 1.30 1.50 1.38

Competitive Comparison

For the Medical Devices subindustry, Edwards Lifesciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences Cash Ratio Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's Cash Ratio falls into.



Edwards Lifesciences Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Edwards Lifesciences's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1644.5/1195.4
=1.38

Edwards Lifesciences's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1644.5/1195.4
=1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Edwards Lifesciences  (NYSE:EW) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Edwards Lifesciences Cash Ratio Related Terms

Thank you for viewing the detailed overview of Edwards Lifesciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Edwards Lifesciences (Edwards Lifesciences) Business Description

Address
One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
Executives
Bobo Donald E Jr officer: CVP,Strategy/Corp Development C/O EDWARDS LIFESCIENCES, ONE EDWARDS WAY, IRVINE CA 92614
Michael A Mussallem director, officer: Chairman & CEO C/O EDWARDS LIFESCIENCES CORP, ONE EDWARDS WAY, IRVINE CA 92614
Scott B. Ullem officer: CVP, CFO C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Daveen Chopra officer: CVP, Surgical Structural Heart C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92618
Larry L Wood officer: CVP, THV Replacement C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Catherine M. Szyman officer: CVP, Critical Care C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Wayne Markowitz officer: GM & SVP, Surgical ONE EDWARDS WAY, IRVINE CA 92614
Heisz Leslie Stone director C/O PUBLIC STORAGE, 701 WESTERN AVENUE, GLENDALE CA 91201
Jean-luc M Lemercier officer: CVP, EMEA, Canada, Latin Amer C/O ONE EDWARDS WAY, IRVINE CA 92614
Sellers Robert W.a. officer: VP, Corp. Controller (Principa ONE EDWARDS WAY, IRVINE CA 92614
Bernard J Zovighian officer: CVP, Surgical Heart Valves C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Huimin Wang officer: CVP, Japan & Intercontinental C/O EDWARDS LIFESCIENCES, ONE EDWARDS WAY, IRVINE CA 92614
Martha H. Marsh director 9769 WEXFORD CIRCLE, GRANITE BAY CA 95746
Kieran Gallahue director PO BOX 684369, PARK CITY UT 84068
Nicholas J Valeriani director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614